OmniAb
5980 Horton Street
Suite 600
Emeryville
CA
94608
United States
Website: https://www.omniab.com/
Email: bd@omniab.com
About OmniAb
OmniAb, Inc.’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence™ (BI) of our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic® (transgenic rat) and OmniClic® (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur™ features unique structural attributes of cow antibodies for complex targets.
We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies with superior performance and developability characteristics.
An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities in emerging target classes. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others.
The OmniAb suite of technologies span from BI-powered repertoire generation to cutting edge antibody discovery and optimization offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.
25 articles about OmniAb
-
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
3/20/2024
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.
-
OmniAb to Report Fourth Quarter 2023 Financial Results on March 20
2/26/2024
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Wednesday, March 20, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
-
OmniAb to Participate in Two Investor Conferences in March
2/20/2024
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in March.
-
OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference
12/14/2023
OmniAb, Inc. (Nasdaq: OABI) announces the presentation of new scientific data on its OmnidAb™ platform, the industry’s first and only transgenic chicken host system producing single domain antibodies (sdAbs), at the 2023 Antibody Engineering & Therapeutics Conference underway in San Diego and hosted by The Antibody Society.
-
OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today’s Research & Technology Virtual Event
11/9/2023
OmniAb, Inc. held its first Research & Technology virtual event earlier , during which members of the management team reviewed the Company’s technology offerings and highlighted the launch of OmnidAb, the industry’s first and only transgenic chicken producing single domain antibodies.
-
OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights
11/9/2023
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and partner program updates.
-
OmniAb to Participate in Two Investor Conferences in November 2023
11/2/2023
OmniAb, Inc. announced that management will be participating in two upcoming investor conferences in November.
-
OmniAb Appoints Steve Love to its Board of Directors
11/1/2023
OmniAb, Inc. announced the appointment of Steve Love to its Board of Directors.
-
OmniAb Announces Agenda for its Research & Technology Virtual Event
10/31/2023
OmniAb, Inc. announces the agenda for its Research & Technology virtual event to be held on Thursday, November 9th beginning at 11:00 a.m. Eastern time.
-
OmniAb to Hold Research & Technology Virtual Event on November 9
10/12/2023
OmniAb, Inc. (Nasdaq: OABI) today announced it will hold a virtual Research & Technology event on Thursday, November 9 beginning at 11:00 a.m. Eastern time.
-
OmniAb to Participate in Two Investor Conferences in September 2023
9/5/2023
OmniAb, Inc. announced that management will be participating in two upcoming investor conferences in September.
-
OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights
8/10/2023
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner program updates.
-
OmniAb Announces the Passing of Director Sunil Patel
8/7/2023
OmniAb, Inc. announces that Director Sunil Patel passed away suddenly last week.
-
OmniAb to Report Second Quarter 2023 Financial Results on August 10
7/31/2023
OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 10, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
-
OmniAb Reports First Quarter 2023 Financial Results and Business Highlights
5/11/2023
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2023, and provided operating and partner program updates.
-
OmniAb to Report First Quarter 2023 Financial Results on May 11
5/1/2023
OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three months ended March 31, 2023 before the open of the U.S. financial markets on Thursday, May 11, 2023 and will hold a conference call that same day beginning at 8:30 a.m. Eastern time.
-
OmniAb to Participate in Upcoming Investor Conferences in May
4/25/2023
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five upcoming investor conferences in May.
-
OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
3/30/2023
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program updates.
-
OmniAb to Report Fourth Quarter 2022 Financial Results on March 30
3/9/2023
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, March 30, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
-
OmniAb to Participate in Three Upcoming Investor Conferences
2/7/2023
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three upcoming investor conferences.